EUROLyser is a diagnostics company based in Salzburg (Germany). It develops engineering and design of Point-of-Care Testing (‘PoCT’) devices as well as test kits sold primarily in Germany and Europe. The products are based on a patented technology and design enabling a multitude of clinical chemistry tests to be developed. EUROLyser‘s patented cartridge technology is based on the use of the same gold standard reagents that are used in large laboratories. As a result, customers are able to obtain the same level of quality in test results as they could expect from large laboratories.

EUROLyser markets its’ products to physicians offices. It also develops OEM partnerships to expand its portfolio into new therapeutic areas, including an ongoing partnership with SALADAX USA who are using Eurolyser’s platform for anti-psychotic drug monitoring (Clozapine).

www.eurolyser.com

INVESTMENT DATE
2019

SECTOR
Diagnostics

TRANSACTION TYPE 
Buy-Out

GROWTH THEME
Internationalisation / Innovation

LOCATION
Germany